Does surgically resected small‐cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?

by Yuqing Lou, Runbo Zhong, Jianlin Xu, Rong Qiao, Jiajun Teng, Yanwei Zhang, Xueyan Zhang, Tianqing Chu, Hua Zhong, Baohui Han
Published 2020-05-01

Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung

by Yanan Wang, Fangfei Qian, Ya Chen, Zhengyu Yang, Minjuan Hu, Jun Lu, Yanwei Zhang, Wei Zhang, Lei Cheng, Baohui Han
Published 2021-09-01

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study

by Qing Chang, Huiping Qiang, Jialin Qian, Yuqiong Lei, Jiahuan Lu, Hui Feng, Yiming Zhao, Baohui Han, Yanwei Zhang, Tianqing Chu
Published 2021-04-01

MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer.

by Rong Li, Xia Pu, Joe Y Chang, Yuanqing Ye, Ritsuko Komaki, John D Minna, Jack A Roth, Baohui Han, Xifeng Wu
Published 2016-01-01

Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases

by Rong Qiao, Runbo Zhong, Jianlin Xu, Yanwei Zhang, Bo Zhang, Shuyuan Wang, Yuqing Lou, Dongfang Chen, Qing Chang, Yizhuo Zhao, Baohui Han
Published 2019-03-01

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

by Jun Lu, Qin Shi, Lele Zhang, Jun Wu, Yuqing Lou, Jie Qian, Bo Zhang, Shuyuan Wang, Huimin Wang, Xiaodong Zhao, Baohui Han
Published 2019-09-01

Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients

by Anning Xiong, Wei Nie, Yan Zhou, Changhui Li, Kai Gu, Ding Zhang, Shiqing Chen, Fengcai Wen, Hua Zhong, Baohui Han, Xueyan Zhang
Published 2021-09-01

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

by Jun Lu, Wei Xu, Jie Qian, Shuyuan Wang, Bo Zhang, Lele Zhang, Rong Qiao, Minjuan Hu, Yiming Zhao, Xiaodong Zhao, Baohui Han
Published 2019-03-01

Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.

by Wenting Wu, Huan Li, Huibo Wang, Xueying Zhao, Zhiqiang Gao, Rong Qiao, Wei Zhang, Ji Qian, Jiucun Wang, Hongyan Chen, Qingyi Wei, Baohui Han, Daru Lu
Published 2012-01-01

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

by Changhui Li, Wei Nie, Jingdong Guo, Anning Xiong, Hua Zhong, Tianqing Chu, Runbo Zhong, Jianlin Xu, Jun Lu, Xiaoxuan Zheng, Bo Zhang, Yinchen Shen, Feng Pan, Baohui Han, Xueyan Zhang
Published 2021-05-01

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial...

by Ying Cheng, Baohui Han, Kai Li, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Jianxing He, Yuankai Shi, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin, Baolan Li, Jing Zhu
Published 2020-04-01

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)

by Caicun ZHOU, Jie WANG, Hong BU, Baocheng WANG, Baohui HAN, You LU, Zhehai WANG, Bo ZHU, Ziping WANG, Qibin SONG, Shengxiang REN, Dongmei LIN, Yayi HE, Xiaohua HU, Hongyun ZHAO, Shukui QIN
Published 2020-02-01

hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527

by Changhui Li, Jiaqi Zhang, Xiaohua Yang, Cheng Hu, Tianqing Chu, Runbo Zhong, Yinchen Shen, Fang Hu, Feng Pan, Jianlin Xu, Jun Lu, Xiaoxuan Zheng, Hai Zhang, Wei Nie, Baohui Han, Xueyan Zhang
Published 2021-08-01

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303

by Xiaoyan Si, Li Zhang, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Baohui Han, Kai Li, Qiming Wang, Jianhua Shi, Zhehai Wang, Ying Cheng, Yuankai Shi, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin
Published 2019-03-01

Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.

by Xueying Zhao, Shiming Wang, Junjie Wu, Xiaoying Li, Xun Wang, Zhiqiang Gao, Wenting Wu, Haijian Wang, Jiucun Wang, Ji Qian, Ke Ma, Hui Li, Baohui Han, Chunxue Bai, Qiang Li, Wenbin Liu, Daru Lu
Published 2015-01-01

Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial

by Tianqing Chu, Jun Lu, Minghong Bi, Helong Zhang, Wu Zhuang, Yan Yu, Jianhua Shi, Zhendong Chen, Xiaochun Zhang, Qisen Guo, Quan Liu, Huijuan Wu, Jian Fang, Yi Hu, Xiuwen Wang, Cuicui Han, Kai Li, Baohui Han
Published 2021-08-01

A Study on the Long-term Non-small Cell Lung Cancer Survivors 
in the Expand Access Program of Gefitinib in China

by Longyun LI, Wei ZHONG, Meilin LIAO, Li CHEN, Baohui HAN, Zhongzhen GUAN, Shiying YU, Xuyi LIU, Yilong WU, Guoliang JIANG, Jianming XU, Jia CHEN, Min TAO, Rongcheng LUO, Weimin LI, Nong XU, Xiao ZHAO, Mengzhao WANG
Published 2012-06-01

Chinese Guidelines on the Diagnosis and Treatment of Primary Lung Cancer 
(2011 Version)

by Xiuyi ZHI, Yilong WU, Shenglin MA, Tianyou WANG, Changli WANG, Jie WANG, Yuankai SHI, You LU, Lunxu LIU, Deruo LIU, Donghong CHEN, Yue YANG, Xiang DU, Hong BU, Qinghua ZHOU, Gening JANG, Baohui HAN, Gang CHENG, Ying CHENG, Shunchang JIAO
Published 2012-12-01

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

by Jing Wang, Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhujun Liu, Baohui Han, Kai Li
Published 2018-12-01

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALT...

by Jianhua Shi, Guimin Chen, Haitao Wang, Xiuxiu Wang, Baohui Han, Kai Li, Qiming Wang, Li Zhang, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhian Liu
Published 2021-09-01